4//SEC Filing
HAUSMAN DIANA 4
Accession 0001725160-24-000036
CIK 0001725160other
Filed
Feb 4, 7:00 PM ET
Accepted
Feb 5, 7:16 PM ET
Size
7.8 KB
Accession
0001725160-24-000036
Insider Transaction Report
Form 4
HAUSMAN DIANA
Director
Transactions
- Award
Stock Option (Right to Buy)
2024-02-01+337,500→ 337,500 totalExercise: $11.69Exp: 2034-01-31→ Common Stock (337,500 underlying) - Award
Common Stock
2024-02-01+337,500→ 377,232 total
Footnotes (2)
- [F1]Represents restricted stock units ("RSUs") granted to the Reporting Person in connection with Reporting Person's previously disclosed appointment as Chief Medical Officer, effective January 19, 2024. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in substantially equal annual installments over a four year period following the vesting commencement date of January 19, 2024, subject to the Reporting Person's continued service with the Issuer.
- [F2]The options were granted to the Reporting Person in connection with Reporting Person's previously disclosed appointment as Chief Medical Officer, effective January 19, 2024. The options will vest over four years in equal monthly installments from the vesting commencement date of January 19, 2024 until the options are fully vested, subject to the Reporting Person's continued service with the Issuer.
Documents
Issuer
Zentalis Pharmaceuticals, Inc.
CIK 0001725160
Entity typeother
Related Parties
1- filerCIK 0001563992
Filing Metadata
- Form type
- 4
- Filed
- Feb 4, 7:00 PM ET
- Accepted
- Feb 5, 7:16 PM ET
- Size
- 7.8 KB